✦ LIBER ✦

I-97. Clinical benefit in NSCLC: The evidence for Gefitinib (“Iressa”)

✍ Scribed by Lynch, Thomas

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical benefit in NSCLC: the evidence

✍ Lynch, Thomas 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 111 KB

P-449 FDG-PET SCAN in the evaluation of

✍ Miwa, Toshiro; Kashii, Tatsuhiko; Oda, Hirofumi; Fujita, Tadashi; Fujishita, Tak 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 176 KB

P-975 The results of the treatment with

✍ Skrickova, J.; Tomiskova, M.; Svobodnik, A.; Kaplanova, J.; Kadlec, B.; Palkova, 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 140 KB

O-243 Clinical benefits in patients with

✍ Janne, Pasi A.; Gurubhagavatula, Sarada; Lucca, Joan; Ostler, Patricia; Skarin, 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 193 KB

O-103 A comparison of the antitumour eff

✍ Natale, R.; Bodkin, D.; Govindan, R.; Sleckman, B.; Rizvi, N.; Capo, A.; Germonp 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 143 KB

Ocular findings in patients with solid t

✍ Murray, P I; Bristow, E; Forsythe, B J; Faulkner, K; Tullo, A B; Esmaeli, B 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 187 KB